Mesothelioma Clinical Trial Testing New INBRX-109 Antibody

A new clinical trial is testing an innovative approach to immunotherapy that could change the way antibodies target pleural mesothelioma tumors. Researchers at eight cancer centers across the U.S. are examining the safety and efficacy of INBRX-109, a unique antibody structure developed to bind with and destroy mesothelioma tumor cells without harming healthy tissue. Enrollment for mesothelioma patients is ongoing for the second stage of the first-in-humans trial. Safety and efficacy reports are expected in the second quarter of 2020. The first stage of the trial reached its endpoint with no reports of toxicity or intolerance after dose escalation in the first 20 patients. New Kind of Antibody and Immunotherapy Inhibrx, a clinical-stage biotechnology company, is sponsoring the clinical trial. The California-based company developed sdAb, a proprietary single domain antibody platform. In this trial, sdAb targets and activates a receptor called Death Receptor 5 (DR5) on tumor cells. Activation of DR5 causes cells to self-destruct and results in killing the tumor. However, overactivation of DR5 causes cell death in normal tissues, especially in the liver. Inhibrx’s new sdAb, labeled INBRX-109, is engineered to only activate the exact number of DR5 receptors that lead to tumor death in mesothelioma cancer cells, while preserving normal cells. Dr. Katherine Kim, the associate director of research at the Cancer Center of Southern California, discussed the study with The Mesoth...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Publication date: Available online 12 July 2020Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Sumit Sahni, Christoph Krisp, Mark P. Molloy, Christopher Nahm, Sarah Maloney, Josef Gillson, Anthony J. Gill, Jaswinder Samra, Anubhav Mittal
Source: Biochimica et Biophysica Acta (BBA) General Subjects - Category: Biochemistry Source Type: research
Analyst, 2020, Accepted Manuscript DOI: 10.1039/D0AN01011A, PaperXiaonan Gao, Congcong Zhao, Keyan Wei, Bo Hu, Yu-Qin Chen, Kehua Xu, Bo Tang The anticancer mechanism for reduced/oxidized ascorbic acid (AA/DHA) is of great significance for clinical cancer therapies. A pH controlled fluorescent nanocarrier was designed to targetable deliver AA and DHA into... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Authors: Skewes MC, Gonzalez VM, Gameon JA, FireMoon P, Salois E, Rasmus SM, Lewis JP, Gardner SA, Ricker A, Reum M Abstract American Indian and Alaska Native (AI/AN) communities experience notable health disparities associated with substance use, including disproportionate rates of accidents/injuries, diabetes, liver disease, suicide, and substance use disorders. Effective treatments for substance use are needed to improve health equity for AI/AN communities. However, an unfortunate history of unethical and stigmatizing research has engendered distrust and reluctance to participate in research among many Native co...
Source: American Journal of Community Psychology - Category: Psychiatry Tags: Am J Community Psychol Source Type: research
Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.
Source: The Scientist - Category: Science Tags: Infographics Magazine Issue Source Type: news
A study suggests the potential for a noninvasive diagnostic that could detect tumors early and differentiate between disease types.
Source: The Scientist - Category: Science Tags: The Literature Source Type: news
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Source: The Scientist - Category: Science Tags: Features Magazine Issue Source Type: news
Publication date: Available online 12 July 2020Source: Pathology - Research and PracticeAuthor(s): Eric Gyan, Linda Ahenkorah Fondjo, William Owiredu, Andrew Jackson, Andrew Green
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 11 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Eun Ji Choi, Nam Jin Yoo, Sug Hyung Lee
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Dear Member of Congress: The 133 undersigned national business, higher education, scientific, patient, and other organizations write to strongly urge you to pass an omnibus FY2015 appropriations bill this year that includes increased investments in scientific research and higher education needed to help close our nation's innovation deficit. Members of the Senate and House from both political parties have highlighted the need to address the innovation deficit. Congress has already taken some preliminary steps in this direction. In most instances, individual appropriations bills considered by the House and Senate Appropri...
Source: ActionBioscience - Category: Science Authors: Source Type: news
More News: Asbestosis | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Contracts | Environmental Health | Hepatitis | Hospitals | Immunotherapy | Liver | Liver Disease | Mesothelioma | Neoadjuvant Therapy | Study | Toxicology | Urology & Nephrology